Allergic bronchopulmonary aspergillosis
ICD-10 B44.81 is a billable code used to indicate a diagnosis of allergic bronchopulmonary aspergillosis.
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to the fungus Aspergillus, primarily Aspergillus fumigatus. It typically occurs in individuals with asthma or cystic fibrosis and is characterized by recurrent episodes of wheezing, coughing, and shortness of breath. The condition is marked by an exaggerated immune response to the fungal spores, leading to airway inflammation and bronchial obstruction. Patients may present with elevated serum IgE levels and specific IgE antibodies to Aspergillus. Diagnosis is often confirmed through clinical history, imaging studies showing central bronchiectasis, and sometimes bronchoscopy with biopsy. Treatment involves the use of corticosteroids to reduce inflammation and antifungal medications, such as itraconazole, to manage fungal colonization. In immunocompromised patients, the risk of developing ABPA is heightened, necessitating careful monitoring and management to prevent severe respiratory complications.
Detailed patient history, including asthma or cystic fibrosis status, and results of allergy testing.
Patients with asthma exacerbations, recurrent respiratory infections, or those with a history of cystic fibrosis.
Documentation must clearly differentiate ABPA from other respiratory conditions and include treatment response.
Comprehensive allergy testing results, including IgE levels and specific fungal sensitivities.
Patients presenting with allergic symptoms and a known history of exposure to Aspergillus.
Focus on the immunological aspects of the condition and the patient's overall immune status.
Used to assess lung function in patients with suspected ABPA.
Document the reason for testing and results.
Pulmonologists should ensure tests are relevant to the patient's respiratory condition.
Common symptoms include wheezing, coughing, shortness of breath, and sometimes hemoptysis. Patients may also experience fever and malaise.
Diagnosis typically involves a combination of clinical history, elevated serum IgE levels, specific IgE testing for Aspergillus, and imaging studies showing bronchiectasis.
Treatment usually includes corticosteroids to reduce inflammation and antifungal medications such as itraconazole to manage fungal colonization.
